Cyclo Therapeutics (CYTH)
(Delayed Data from NSDQ)
$1.08 USD
-0.02 (-1.82%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.11 +0.03 (2.78%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CYTH 1.08 -0.02(-1.82%)
Will CYTH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CYTH based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CYTH
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer?s Disease from European Patent Office
Cyclo Therapeutics granted patent by European Patent Office
One new option listing and eighteen option delistings on July 22nd
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results